Follow on Google News News By Tag * Formulation * Tablets And Capsules * Solid Oral Dose * Contract Pharmaceutical * Pharmaceutical * More Tags... Industry News News By Place Country(s) Industry News
Follow on Google News | Metrics Contract Services scientist awarded patent for zero-order release tablet technologyDr. Brad Gold, vice president of pharmaceutical development, has received a U.S. patent for his intellectual property about controlled release technology
By: Metrics Inc. The U.S. Patent and Trademark Office awarded Dr. Thomas B. “Brad” Gold a patent (No. 8,858,993) for his application, “Coated tablets with zero-order or near zero-order release kinetics.” Gold’s intellectual property centers on formulation development technology that allows for the steady, continuous release of active pharmaceutical ingredient (API) during a particular duration of time, so that a patient won’t experience variations or spikes of the medication’s therapeutic benefit. “For a drug with a 12-hour release profile, for example, the tablet would release 100 percent of the API steadily throughout that time period without any drop offs or spikes, which sometimes occur with other modified release technologies,” Gold’s patent application builds upon osmotic techniques used to deliver soluble and insoluble large- or small-molecule drugs. Heretofore, true osmotic delivery relied on a matrix tablet with complex manufacturing needs – such as, for example, the application of a solvent for the coating, the need to drill an orifice into the coating, and specialized equipment. “The manufacturing of osmotic tablets is difficult, not very practical and expensive -- and for that reason, not many companies do it,” Gold explained. By contrast, Gold’s innovation provides osmotic-like delivery benefits without the accompanying manufacturing challenges. Gold’s patented zero-order release technology uses direct compression, three to five excipients plus the active pharmaceutical ingredient (API), and a much simpler coating – so that the tablet behaves similarly to an osmotic release tablet. “Our technology offers the advantage of ease of manufacturing using standard industry processes and equipment,” he said. John S. Ross, executive vice president of Metrics, said the patent reflects the kind of thoughtful scientific leadership that Gold and his colleagues apply to their work each day. The formulation development scientists at Metrics offer a depth of relevant experience that enables them to identify solutions to clients’ most challenging pharmaceutical projects, he said. “For 20 years, pharma companies have consistently turned to Metrics for help in effectively delivering the full therapeutic benefit of their latest drug discoveries,” About Metrics Contract Services Metrics Contract Services is a full-service pharmaceutical development and manufacturing organization serving clients worldwide. We deliver proven scientific and operational excellence for solid oral dosage forms. Our areas of expertise include quality formulation development; Located in Greenville, N.C., Metrics Contract Services is a proud member of the Mayne Pharma family. Learn more online. About Mayne Pharma Mayne Pharma is a publicly traded specialty pharmaceutical company listed on the Australian Securities Exchange. The company develops and manufactures branded and generic product globally – either directly or through distribution partners – while applying its drug-delivery expertise for contract development and manufacturing services. Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems, and these technologies have been successfully commercialized in numerous products that have been marketed around the world. Mayne Pharma has drug development and manufacturing facilities in Salisbury, Australia, with expertise in formulating complex oral dose forms, including controlled substances, modified release products and inherently unstable compounds. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|